CEO and Managing Director, Michael Johnson, outlines Rhinomed's rapid growth and global presence, and how it is targeting the large addressable markets in sport, sleep, nausea, allergy/congestion and respiratory issues. An exciting Melbourne company, Michael discusses Rhinomed's recent achievements, future prospects and strategic goals for the coming year.
Rhinomed Limited (ASX.RNO) is a ASX listed airway technology company that has developed a simple and innovative nasal stent to improve air flow to the lungs and deliver therapeutic agents. The Company has established a leading position in sports performance enhancement, as testified by athletes including two-time Tour de France winner Chris Froome.
Any advice contained within this presentation is general advice and does not consider your objectives, financial situation or needs, and you should consider whether it’s appropriate for you. The information we are giving you is for educational purposes only.
Accurate time of recording, 17 June 2020 at 12pm AEST.